The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ORGANIZATION
ORGANIZATION
- OTC Industry Group to Up Its Efforts to Reduce “Switch Lag”
May 22, 2019
- Sales of Japan CRO Association Members Down 1.2% to 190 Billion Yen in 2018; Pharma Sales Up 2.6%
May 22, 2019
- Wholesaler Group to Set Up Own Rules for Information Provision by Autumn
May 21, 2019
- Kymriah’s 33.5 Million Yen Price Tag Favorably Received by JMA
May 16, 2019
- Payer Reps Stress Need to Revise Coverage of Drugs for Minor Illnesses; Kymriah’s Price Isn’t Necessarily too High
May 16, 2019
- Number of Contract Sales Reps Down 11.5% in FY2018: JCSOA
April 19, 2019
- GHIT Fund to Leverage Japanese Technology to Benefit Neglected Patients around the World: New CEO
April 18, 2019
- Regenerative Medicine Groups in Asia Begin Discussions towards Mutual Approval
April 15, 2019
- JPMA Not Envisioning Asia-Version EMA at This Point: Chief
April 11, 2019
- Drug Damage Watchdog Nudges Govt, Shionogi to Suspend Xofluza Sales
April 10, 2019
- Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding
April 9, 2019
- Patient Groups Press for Emergency Import of Methotrexate amid Tight Supply
April 8, 2019
- Hodanren Calls for Transparency in Kymriah Pricing Process
April 8, 2019
- No More Nonprescription Switches for Lifestyle Disease Drugs, Says JMA Exec
April 5, 2019
- Generic Use Rate at 74.7% in October-December 2018: JGA
March 29, 2019
- BMS Exec Ohura Appointed as CEO of GHIT Fund
March 29, 2019
- JPMA Poised to Continue Pitching Drugs’ Multi-Faceted Values to Politicians: Director General
March 25, 2019
- 2020 Drug Price Revision Is Focus Issue for FPMAJ in FY2019 Plan
March 25, 2019
- FPMAJ Wants Asian Equivalent of EMA, Chairman Stresses Merit of Blanket Approval
March 20, 2019
- EFPIA Official Prods Japan to Limit CEA Application to Financially Impactful Drugs
March 19, 2019
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…